Duopharma Biotech BhdXKLS:7148 +2.48%83 PEG Ratio is 1.52 as of Jul. 04, 2026, which is 61% below its 10-year median of 3.91. GuruFocus rates XKLS:7148 with a GF Score™ of 83/100 and a GF Value™ of RM1.53 (Modestly Undervalued). The stock has 4 warning signs investors should review. Among 349 Drug Manufacturers companies, Duopharma Biotech Bhd ranks better than 54.15% on this metric.
* The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.
The historical rank and industry rank for Duopharma Biotech Bhd's PEG Ratio or its related term are showing as below:
XKLS:7148'
s PEG Ratio Range Over the Past 10 Years
Min: 1.27 Med: 3.91 Max: 21.45
Current: 1.52
During the past 13 years, Duopharma Biotech Bhd's highest PEG Ratio was 21.45. The lowest was 1.27. And the median was 3.91.
XKLS:7148's PEG Ratio is ranked better than 54.15% of 349
companies
in the Drug Manufacturers industry
Industry Median: 1.71
vs XKLS:7148: 1.52
Peter Lynch thinks a company with a P/E ratio equal to its growth rate is fairly valued.
Duopharma Biotech Bhd (XKLS:7148) PEG Ratio Explanation
To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the P/E ratio divided by the growth ratio. He thinks a company with a P/E ratio equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a P/E of 20, instead of a company growing 10% a year with a P/E of 10.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XKLS:7148 vs ZTS, UTHR, VTRS: PEG Ratio Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Duopharma Biotech Bhd's PEG Ratio, along with its competitors' market caps and PEG Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Duopharma Biotech Bhd PEG Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Duopharma Biotech Bhd's PEG Ratio distribution charts can be found below:
* The bar in red indicates where Duopharma Biotech Bhd's PEG Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Note: The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.
Duopharma Biotech Bhd (XKLS:7148) has a PEG Ratio of 1.52 as of Jul. 04, 2026. Price-earnings to growth ratio is the ratio of price-earnings to a company's earnings growth rate. View historical data on Duopharma Biotech Bhd and its competitors. This is 61% below median its historical median of 3.91. Over the past decade, Duopharma Biotech Bhd's PEG Ratio has ranged from 1.27 to 21.45. According to the industry distribution chart, Duopharma Biotech Bhd ranks #160 out of 349 companies in the Drug Manufacturers industry, placing it in the top 45.8%.
Is Duopharma Biotech Bhd's PEG Ratio too high?
Duopharma Biotech Bhd's current PEG Ratio of 1.52 is 61% below median its 10-year median of 3.91. Over the past 10 years, this metric has ranged from a low of 1.27 to a high of 21.45. The Drug Manufacturers industry median PEG Ratio is 1.71. Duopharma Biotech Bhd's value of 1.52 is 11.1% below this industry median. Based on the distribution chart, Duopharma Biotech Bhd ranks #160 out of 349 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Duopharma Biotech Bhd has a GF Score™ of 83/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Duopharma Biotech Bhd's PEG Ratio compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Duopharma Biotech Bhd ranks #160 out of 349 companies for PEG Ratio. This puts Duopharma Biotech Bhd in the upper half of its industry. The industry median PEG Ratio is 1.71. Duopharma Biotech Bhd's value of 1.52 is 11.1% below this benchmark. Historically, Duopharma Biotech Bhd's own PEG Ratio has ranged from 1.27 to 21.45 over the past decade. While the company's 10-year median is 3.91 vs. the industry median of 1.71, Duopharma Biotech Bhd has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PEG Ratio for a Drug Manufacturers company?
The median PEG Ratio among Drug Manufacturers companies is 1.71, based on 349 companies in the industry. Companies in the top quartile (top 25%) have a PEG Ratio significantly above this median, while those in the bottom quartile fall well below. However, PEG Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Duopharma Biotech Bhd's current PEG Ratio of 1.52 is 11.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PEG Ratio mean?
A high PEG Ratio can signal that a stock is expensive relative to its fundamentals. Price-earnings to growth ratio is the ratio of price-earnings to a company's earnings growth rate. View historical data on Duopharma Biotech Bhd and its competitors. For the Drug Manufacturers industry, the median PEG Ratio is 1.71 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Duopharma Biotech Bhd's current PEG Ratio is 1.52, which is 61% below median its own 10-year median of 3.91. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Duopharma Biotech Bhd stock overvalued right now?
Based on GuruFocus' analysis, Duopharma Biotech Bhd (XKLS:7148) is currently considered Modestly Undervalued. The stock's GF Value™ is RM1.53, compared to a current price of RM1.24 — trading 19% below its estimated fair value. The current PEG Ratio is 1.52, which is 61% below median its 10-year median of 3.91 and 11.1% below the Drug Manufacturers industry median of 1.71. Duopharma Biotech Bhd's overall GF Score™ is 83/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PEG Ratio calculated?
PEG Ratio is calculated from a company's financial statements. For Duopharma Biotech Bhd (XKLS:7148), the current PEG Ratio is 1.52 as of Jul. 04, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Duopharma Biotech Bhd (XKLS:7148) Overvalued in 2026?
Based on GuruFocus' analysis, Duopharma Biotech Bhd stock appears to be undervalued.
The current stock price of RM1.24 is trading 19% below its estimated GF Value™ of RM1.53.
GuruFocus considers Duopharma Biotech Bhd to be Modestly Undervalued.
Key valuation signals for XKLS:7148:
PEG Ratio: 1.52 (61% below median its 10-year median of 3.91)
GF Value™: RM1.53 vs. price of RM1.24 (19% below fair value)
Industry Position: 11.1% below the Drug Manufacturers median (#160 of 349)
No single metric tells the full story. See the XKLS:7148 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Duopharma Biotech Bhd is an investment holding company engaged in manufacturing pharmaceuticals. The company develops, manufactures, and markets generic and over-the-counter pharmaceutical products. The operating segment of the company is the manufacturing and distribution of pharmaceutical products. The principal activities of its subsidiary are to carry out business as a manufacturer, distributor, importer, and exporter of pharmaceutical products and medicines. Geographically, the company generates the majority of its revenue from Malaysia.
83GF Score
Get the complete analysis for XKLS:7148
PEG Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XKLS:7148 has been successfully added to your 
